MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001821

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2026

Nucleos(t)ide withdrawal versus nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B trial).

Thursz Mark, Lemoine Maud, Brown Ashley, Carey Ivana, Message Jack, Kennedy Patrick, Forton Daniel, Wiselka Martin, Aldersley Mark, Prince Martin, McPherson Stuart, Phillips Sandra, Chokshi Shilpa, Burton Alice, Maini Mala, Christiaan Botha Johannes, Nastouli Eleni, Tsao Samantha, Falaschetti Emanuela, Box Hanna, Habib Mariam, Agarwal Kaushik, NUC-B Study Group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Finite therapy resulting in sustained hepatitis B surface antigen (HBsAg) loss for patients with chronic HBV infection (CHB) is an important therapeutic goal. In patients with HBeAg-negative infection, nucleos(t)ide analog (NA) withdrawal may achieve HBsAg loss in 5%-20% of patients after 3 years. Pegylated interferon (PEG-IFNα) is a recognized treatment for CHB.

METHODS

NUC-B was a randomized, multicenter trial in NA-treated non-cirrhotic HBeAg-negative patients with CHB. Patients were allocated to either NA withdrawal alone (control) or NA withdrawal followed by a 16-week course of PEG-IFNα 180 μg weekly commencing 4 weeks after NA cessation (PEG-IFNα). The primary endpoint was HBsAg loss at 3 years.

RESULTS

The target recruitment of 240 patients was not achieved. In all, 156 patients, 82 to the control arm, 74 to the PEG-IFNα arm, were recruited between 2017 and 2021; median age 45 years, 24% female, HBV genotypes-A 16%, B 6%, C 4%, D 24%, E 22%, other 1%, ānd unknown 26%. At 3 years, 3% of patients in the control arm and 14% of patients in the PEG-IFNα arm lost HBsAg (OR 5.39; 95% CI (1.11, 26.19); p =0.037). In the control arm, 34.9% of patients returned to NA therapy compared with 28.4% in the PEG-IFNα arm. Exaggerated flares occurred in 27.9% of patients in the control arm compared with 13.4% in the PEG-IFNα arm.

CONCLUSIONS

The use of adjuvant PEG-IFNα therapy after withdrawal of NA therapy increases the rate of HBsAg loss while simultaneously reducing the number of exaggerated flares.

Для цитирования: Thursz Mark, Lemoine Maud, Brown Ashley, Carey Ivana, Message Jack, Kennedy Patrick, Forton Daniel, Wiselka Martin, Aldersley Mark, Prince Martin, McPherson Stuart, Phillips Sandra, Chokshi Shilpa, Burton Alice, Maini Mala, Christiaan Botha Johannes, Nastouli Eleni, Tsao Samantha, Falaschetti Emanuela, Box Hanna, Habib Mariam, Agarwal Kaushik, NUC-B Study Group. Nucleos(t)ide withdrawal versus nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B trial).. Hepatology (Baltimore, Md.). 2026. DOI: 10.1097/hep.0000000000001821.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.